

**Identification and Functional
Characterisation of a Genetic
Subset of Non-Small Cell Lung
Cancer**

Claire Louise Mahoney

July 2009
Clare College

This dissertation is submitted for the degree of Doctor of Philosophy

DECLARATION

This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except where specifically indicated in the text. The dissertation does not exceed the word limit set by the Biology Degree Committee.

ACKNOWLEDGEMENTS

I would like to thank my supervisor Andy Futreal for his help and support over the four years and his keenness to follow the more unusual threads in this project. I would also like to thank my thesis committee Pentao Liu and Nick Coleman for all their comments, help and support. I would like to thank Mike Stratton and past and present members of the Cancer Genome Project who over the years have helped me and become good friends. Special thanks go to Lina Chen for her help with the statistical analysis of the gene expression data, Chris Greenman, Gijs van Haaften, Tom Santarius, Jennifer Yen and Wendy McLaughlin. I would also like to thank Jules Griffin from Cambridge University for collaborating and carrying out the NMR spectroscopy. Finally, I would like to thank my family for their support and Phil who has supported and encouraged me throughout the four years.

ABSTRACT

Non-small cell lung cancer (NSCLC) constitutes ~80% of all lung cancer cases. It is often treated with conventional chemotherapy and has survival rates of only 7% at 5 years. Survival rates improve if it is diagnosed early and can be surgically removed, however over half of all cases are at stage IV at diagnosis. There is a need for new therapeutic targets as well as better detection. This project aimed to functionally characterise a new genetic subset of NSCLC characterised by *LKB1* loss and *KRAS* activation (*LKB1null/KRASmut*). The association of mutations is interesting as the signalling pathways are linked by RHEB. Loss of *LKB1* may lead to over activation of RHEB which inhibits wild type BRAF but not mutant BRAF thus blocking MAPK signalling. NSCLC with *LKB1* mutations may therefore have a general requirement for an activation of the MAPK cascade to overcome suppression of MAPK signalling by RHEB. Following from this, subsequent experiments showed this genetic subset to be sensitive to MEK inhibition and mTOR inhibition. The sensitivity to MEK inhibition is not due to downstream effects on cyclin D1 as reported for melanoma. Comparison of gene expression in this genetic subset compared to other NSCLC cell lines revealed a unique expression signature. Analysis of this signature revealed a metabolic profile dominated by truncation of the citric acid cycle at the pyruvate dehydrogenase reaction. We further characterised these cells using ¹³C and proton NMR spectroscopy. These data confirmed truncation of the citric acid cycle in the *LKB1/KRAS* mutant subset and suggests this genetic subset of lung cancer creates the Warburg Effect through inactivation of the pyruvate dehydrogenase complex. The NMR spectroscopy highlighted further metabolic changes including the reliance of this subset on both glucose and glutamine metabolism despite the ideal growth conditions of cell culture. The *in vitro* phenotypic data presented in this study make a strong case for these changes being “hard-wired” by the mutation states and thus present further opportunities for their investigation as potential avenues for therapeutic development.

TABLE OF CONTENTS

Declaration	2
Acknowledgements	3
Abstract	4
Table of Contents	5
List of Figures	9
List of Tables	10
1. INTRODUCTION	12
1.1 Cancer	12
1.1.1 Lung Cancer	13
1.2 LKB1/STK11	16
1.2.1 Role of LKB1 in cancer	16
1.2.1.1 LKB1 in hereditary cancer	16
1.2.1.2 LKB1 in somatic cancers	17
1.2.2 LKB1 structure and function	18
1.2.3 LKB1 is a multi-tasking tumour suppressor kinase	20
1.2.4 LKB1 and cell polarity	20
1.2.5 The role of LKB1 in energy sensing and metabolism	22
1.2.5.1 LKB1/AMPK signalling in liver and gluconeogenesis	25
1.2.5.2 LKB1/AMPK signalling in fatty acid metabolism and cholesterol biosynthesis	26
1.2.5.3 AMPK signalling in skeletal muscle and mitochondrial biogenesis	27
1.2.5.4 AMPK as a therapeutic target	28
1.2.6 LKB1/AMPK signal to control protein synthesis and translation through mTOR	30
1.2.6.1 mTOR	31
1.2.6.2 Role of mTOR in translation and protein synthesis	32
1.2.6.3 mTOR as a therapeutic target	33
1.2.7 Role of LKB1 in proliferation and apoptosis	34
1.3 MAPK signalling	36
1.3.1 RAS-MAPK signalling	37
1.3.1.1 RAS	39
1.3.1.2 RAS as a therapeutic target	41
1.3.1.3 RAF	41

1.3.1.4 RAF as a therapeutic target	43
1.3.1.5 Signalling downstream of RAF through MEK/ERK and RSK	43
1.3.1.6 MEK as a therapeutic target	45
1.4 LKB1/AMPK/mTOR and RAS-MAPK pathway crosstalk	47
1.5 Cell lines as model systems for developing therapeutics	49
1.6 Introduction to thesis project	50
2. MATERIALS AND METHODS	51
2.1 Cell culture	51
2.2 Drug assays	51
2.2.1 Cell plating	51
2.2.2 Drug dilutions	54
2.2.3 Drug addition	54
2.2.4 Proliferation assay	55
2.2.5 Data analysis	55
2.3 siRNA knockdown	56
2.3.1 Cell plating	56
2.3.2 Transfection of siRNA	56
2.3.3 Proliferation assay	57
2.3.2 Data analysis	57
2.4 Protein Quantification	57
2.4.1 Cell plating	57
2.4.1.1 To determine the downstream effects of CI-1040 and rapamycin	57
2.4.1.2 To estimate the level of siRNA knockdown	58
2.4.2 Harvesting protein	58
2.4.3 Quantification of protein	58
2.4.4 SDS-PAGE	59
2.4.5 Western blotting	59
2.4.6 Visualisation and data analysis	60
2.5 Analysis of Affymetrix microarray data	61
2.5.1 Data analysis	61
2.5.2 Bioinformatics analysis of genes with significantly different expression	62
2.6 Expression analysis of CI-1040, rapamycin and AMPK inhibitor treated cells	62
2.6.1 Cell plating and drug addition	62
2.6.2 RNA extraction	62
2.6.3 Assessing quality and quantity of RNA	63

2.6.4 Microarray	64
2.6.5 Data analysis	65
2.6.6 Bioinformatics analysis of genes with significantly different expression	65
2.7 NMR spectroscopy	66
2.7.1 Labelling of metabolites with ¹³ C glucose	66
2.7.2 Preparation of samples for NMR spectroscopy	66
2.7.3 Pattern recognition methods	67
3. <i>LKB1</i> MUTATIONS CO-OCCUR WITH <i>KRAS</i> MUTATIONS IN NSCLC AND CONFER SENSITIVITY TO THE MEK INHIBITOR CI-1040 AND THE mTOR INHIBITOR RAPAMYCIN	68
3.1 Introduction	68
3.2 Results	71
3.2.1 <i>LKB1</i> loss co-occurs with <i>RAS-MAPK</i> mutations in NSCLC cell lines	71
3.2.2 Cell lines with inactivation of <i>LKB1</i> and activated <i>KRAS</i> are more sensitive to CI-1040	72
3.2.3 Cell lines with inactivation of <i>LKB1</i> and activated <i>RAS-MAPK</i> pathway are more sensitive to rapamycin	76
3.2.4 Dual inhibition with rapamycin and CI-1040 is neither additive nor synergistic in <i>LKB1/KRAS</i> mutant cell lines	77
3.2.5 Sensitivity of <i>LKB1/KRAS</i> mutant cell lines to CI-1040 is not due to downstream effects on cyclin D1	80
3.2.6 Sensitivity of <i>LKB1/KRAS</i> mutant cell lines to CI-1040 may be due to downstream effects on p70S6K	81
3.3 Discussion	83
4. INVESTIGATION OF A UNIQUE EXPRESSION PROFILE IN <i>LKB1/KRAS</i> MUTANT NSCLC	86
4.1 Introduction	86
4.2 Introduction to metabolism	87
4.2.1 Normal cellular metabolism	87
4.2.2 Cancer cell metabolism	91

4.2.2.1 Alterations to glycolysis in cancer cells	93
4.2.2.2 Other metabolic alterations beyond glycoysis in cancer cells	94
4.3 Results	98
4.3.1 <i>LKB1/KRAS</i> mutant NSCLC cell lines have a unique gene expression profile	99
4.3.2 Investigation into the role of the pentose phosphate pathway in <i>LKB1/KRAS</i> mutant NSCLC cell lines	105
4.3.3 PDK4 and investigation into its role in the Warburg Effect through inhibition of the pyruvate dehydrogenase complex	107
4.3 Discussion	117
5. MICROARRAY ANALYSIS OF CELL LINES TREATED WITH CI-1040, RAPAMYCIN AND AMPK INHIBITOR COMPOUND C	121
5.1 Introduction	121
5.2 Outline of experiment plan	121
5.3 Results	123
5.3.1 Expression analysis following CI-1040 treatment	123
5.3.2 Expression analysis following rapamycin treatment	129
5.3.3 Effects of AMPK inhibition on proliferation and gene expression	133
5.4 Discussion	140
6. FUNCTIONAL ANALYSIS OF AKR1B10 EXPRESSION IN <i>LKB1/KRAS</i> MUTANT NSCLC	142
6.1 Introduction	142
6.2 Results	146
6.2.1 AKR1B10 protein expression in <i>LKB1/KRAS</i> mutant NSCLC cell lines	146
6.2.2 siRNA knockdown of AKR1B10 does not effect proliferation rate in AKR1B10 expressing NSCLC cell lines	147
6.2.3 AKR1B10 does not play a role in retinoic acid signalling in NSCLC cell lines	150
6.3 Discussion	155
7. GENERAL DISCUSSION	157
REFERENCES	165
APPENDIX A	212

LIST OF FIGURES

Figure 1-1 AMPK structure and regulation	24
Figure 1-2 Simplified overview of the known components of the LKB1/AMPK/mTOR pathways	29
Figure 1-3 Simplified overview of RAS-MAPK signalling	38
Figure 1-4 Simplified overview of the known signalling crosstalk between the LKB1/AMPK/mTOR pathway and the RAS-MAPK pathway	48
Figure 3-1 Simplified snapshot of crosstalk between LKB1 and RAS-MAPK signalling pathways	70
Figure 3-2 Venn diagram showing the overlap of <i>LKB1</i> , <i>KRAS</i> and <i>BRAF</i> mutations in 87 NSCLC cell lines	72
Figure 3-3 Cell lines with inactivated <i>LKB1</i> and activated <i>KRAS</i> are more sensitive to the MEK inhibitor CI-1040	74
Figure 3-4 Cell lines with inactivated <i>LKB1</i> and activated <i>RAS-MAPK</i> are more sensitive to the mTOR inhibitor rapamycin	76
Figure 3-5 <i>LKB1/KRAS</i> mutant NSCLC cell lines are more sensitive to dual inhibition with CI-1040 and rapamycin	77
Figure 3-6 Dual inhibition with rapamycin and CI-1040 is neither additive nor synergistic	79
Figure 3-7 Sensitivity to the MEK inhibitor in <i>LKB1/KRAS</i> mutant NSCLC cell lines is not due to downstream effects on cyclin D1	81
Figure 3-8 Immunoblot analysis of total p70S6K and phospho-p70S6K(thr-389) in CI-1040 and rapamycin treated cell lines	82
Figure 4-1 The main reactions of glycolysis	89
Figure 4-2 An overview of The Citric Acid Cycle	90
Figure 4-3 Overview of metabolic alterations in proliferating cancer cells	92
Figure 4-4 Regulation of the Pyruvate Dehydrogenase Complex	96
Figure 4-5 <i>LKB1/KRAS</i> mutant cell lines have a distinct expression pattern	99
Figure 4-6 MetaCyc map of the differentially expressed genes in <i>LKB1/KRAS</i> mutant NSCLC cell lines	103
Figure 4-7 <i>LKB1/KRAS</i> mutant NSCLC show overexpression of 3 pentose phosphate pathway genes	104
Figure 4-8 Cell lines with <i>RAS-MAPK</i> alterations are more sensitive to the G6PD inhibitor 6-AN	106
Figure 4-9 Regulation of the pyruvate dehydrogenase complex	108
Figure 4-10 PLS-DA plots	110

Figure 4-11 <i>LKB1/KRAS</i> mutant cell lines produce more lactate than control cell lines	112
Figure 4-12 Simplified overview of glucose and glutamine metabolism	114
Figure 5-1 Heatmap of differentially expressed genes in <i>LKB1/KRAS</i> mutant before and after CI-1040 treatment	124
Figure 5-2 Heatmap of differentially expressed genes in <i>LKB1/KRAS</i> mutant before and after rapamycin treatment	130
Figure 5-3 <i>LKB1/KRAS</i> mutant cell lines are more sensitive to the AMPK inhibitor compound C	134
Figure 5-4 Heatmap of differentially expressed genes in <i>LKB1/KRAS</i> mutant before and after Compound C treatment	137
Figure 6-1 The hypothesised role of AKR1B10 in retinoic acid signalling	145
Figure 6-2 AKR1B10 is expressed in <i>LKB1/KRAS</i> mutant NSCLC cell lines	146
Figure 6-3 Immunoblot of siRNA knockdown of AKR1B10 in NCI-H460 cells	147
Figure 6-4 Relative proliferation rate of NSCLC cell lines 7 days after transfection with siRNA to AKR1B10	149
Figure 6-5 Experimental plan to examine whether AKR1B10 plays a role in RA signalling in NSCLC	151
Figure 6-6 Treatment with beta-carotene has no significant effects on proliferation rate of NSCLC cell lines	152
Figure 6-7 Treatment with 9- <i>cis</i> -retinoic acid has no significant effects on proliferation rate of NSCLC cell lines	153
Figure 6-8 Treatment with All- <i>trans</i> -retinoic acid treatment has no significant effects on proliferation rate of NSCLC cell lines	154

LIST OF TABLES

Table 2-1 Genetic background and histology of the cell lines used in the study	53
Table 2-2 Antibodies used in this study	60
Table 3-1 Statistical significance of <i>LKB1</i> mutations and <i>RAS-MAPK</i> pathway mutations in NSCLC	71
Table 3-2 Mutation status of oncogenes and tumour suppressors known to be commonly mutated in NSCLC for the cell lines treated	73
Table 4-1 The most significantly enriched GO categories are related to Cellular metabolism	102

Table 4-2 Metabolites in ^1H and ^{13}C NMR spectra which are significantly different between <i>LKB1/KRAS</i> mutant cell lines and controls	111
Table 5-1 GO term analysis of differentially expressed genes in <i>LKB1/KRAS</i> mutant cell lines after CI-1040 treatment	127
Table 5-2 5 μM CI-1040 treatment results in altered expression of 26 genes in <i>LKB1/KRAS</i> mutant cell lines 8hrs after treatment	128
Table 5-3 Genes with differential expression in <i>LKB1/KRAS</i> mutant cell lines 8hrs after treatment with 40nM rapamycin	132
Table 5-4 Genes with differential expression in <i>LKB1/KRAS</i> mutant cell lines 8hrs after treatment with 7 μM Compound C	138
Table 5-5 GO term analysis of differentially expressed genes in <i>LKB1/KRAS</i> mutant cell lines after Compound C treatment	139